Vasoactive intestinal peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.
Vasoactive intestinal peptide (VIP) just put itself on the map for cartilage research. A new study shows VIP drives chondrogenesis—basically, it helps stem cells turn into cartilage cells faster and better. This is a big deal for anyone looking at osteoarthritis, where cartilage breakdown is the main problem.
J Mol Med (Berl)
by Tecza K, Rodríguez-Hernández C, Villanueva-Romero R et al.
“Vasoactive intestinal peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis. Tecza K(1), Rodríguez-Hernández C(1), Villanueva-Romero R(1)(2), Castro-Vázquez D(1), Cabrera-Martín A(1), Arribas-Castaño P(1), Carrión M(1)(2), Gutiérrez-Cañas I(1)(2), Largo R(3), Calamia V(4), Blanco FJ(4), Gomariz RP(1), Juarranz Y(1)(2), Martínez C(2)(5), Pérez-García S(6)(7). Author information: (1)Department of Cell Biology and Histology, Faculty of Biological Science, Complutense University of Madrid (ROR 02p0gd045), Madrid, 28040, Spain. (2)San Carlos Health Research Institute (IdISSC) (ROR 04d0ybj29), Musculoskeletal Pathology Group, Madrid, 28040, Spain. (3)Division of Rheumatology, IIS-Fundación Jiménez Díaz (ROR 049nvyb15), Madrid, 28040, Spain. (4)Rheumatology Research Group (GIR), INIBIC-Biomedical Research Institute (ROR 04c9g9234), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, 15006, Spain. (5)Departmental Section of Cell Biology and Histology, Faculty of Medicine, Complutense University of Madrid (ROR 02p0gd045), Madrid, Spain. (6)Department of Cell Biology and Histology, Faculty of Biological Science, Complutense University of Madrid (ROR 02p0gd045), Madrid, 28040, Spain. selene@ucm.es. (7)San Carlos Health Research Institute (IdISSC) (ROR 04d0ybj29), Musculoskeletal Pathology Group, Madrid, 28040, Spain. selene@ucm.es. Current therapies for osteoarthritis (OA) focus on symptom management, rather than halting disease progression. Vasoactive intestinal peptide (VIP) has shown promising effects in musculoskeletal diseases, preserving joint integrity and modulating inflammation. This study investigates the potential of VIP to promote chondrogenic differentiation of human bone marrow mesenchymal stem cells (BM-hMSC) and to modulate inflammatory and cartilage extracellular matrix (ECM)-degrading mediators in human osteoarthritis articular chondrocytes (OA-hAC). BM-hMSC from healthy donors were cultured in 3D pellet sytems under chondrogenic conditions, with or without VIP, for up to 21 days. Chondrogenesis was evaluated through the expression of key markers (SOX9, COL2A1, and ACAN), hypertrophic markers (RUNX2, COL10A1, and MMP13), and glycosaminoglycans (GAG). VIP accelerated chondrogenic differentiation by inducing earlier mRNA and protein expression of chondrogenic markers and enhancing GAG production. In parallel, OA-hAC were cultured in 3D alginate microbeads and stimulated with fibronectin fragments (Fn-fs) in the presence and absence of VIP. We analysed the effects of VIP on cell proliferation, GAG production, and the modulation of complement components (C1R and C3) and matrix metalloproteinases (MMP1, MMP3, MMP9, and MMP13). VIP increased cell proliferation and GAG deposition while significantly reducing the production of complement component C1R and matrix metalloproteinases MMP1 and MMP13. Overall, these findings demonstrate that VIP advances chondrogenesis and exerts anti-inflammatory and anti-catabolic effects in 3D culture models. This study highlights the potential of VIP as a therapeutic agent and supports the combination of MSC-based approaches with VIP as a promising strategy to enhance cartilage regeneration and slow OA progression. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. Conflict of interest statement: Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Hospital Universitario de La Princesa (06-06-24, acta CEIm 11/24). Consent to participate: Informed consent was obtained from all individual participants included in the study. Competing interests: The authors have no relevant financial or non-financial interests to disclose.”
Here’s what the research team did: They took human bone marrow mesenchymal stem cells and put them in 3D pellet cultures. Some got VIP, some didn’t. The ones with VIP fired up chondrogenic markers like SOX9, COL2A1, and ACAN sooner. Glycosaminoglycan (GAG) production—a strong sign of cartilage formation—went up too. If you want cartilage, you want GAG.
But they didn’t stop at stem cells. The team also dropped VIP into cultures of osteoarthritic chondrocytes. They watched for changes in cell proliferation, GAG output, and the “bad actor” molecules that chew up cartilage. Here’s the punchline: VIP boosted cell growth and GAG, but slammed the brakes on complement component C1R and matrix metalloproteinases MMP1 and MMP13. Those two enzymes are notorious for breaking down cartilage in osteoarthritis.
Key takeaway: VIP isn’t just making more cartilage—it’s also dialing down inflammation and the molecular wrecking crew that drives OA.
For researchers, this is a clear signal to look closer at VIP as a research compound. Combining VIP with MSC-based strategies could be the shortcut to better cartilage regeneration and slower OA progression.
Want to dig deeper into the science or see what other peptides are showing promise? Check out the peptide research index. For those sourcing compounds, browse the vendor directory.
VIP: Not just another peptide—potential cartilage game-changer.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.